Skip to main content

Cyclo Therapeutics, Inc.

CYTHDelisted Mar 26, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000922247

Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.

13F holders, Q1 2021

Institutional positions in Cyclo Therapeutics, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
9
No complete 13F data for Q4 2020
Shares held
71.4K
No complete 13F data for Q4 2020
Total value
$585.0K
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 9 institutions
Q1 2021: 9 institutionsQ2 2021: 12 institutionsQ3 2021: 13 institutionsQ4 2021: 15 institutionsQ1 2022: 13 institutionsQ2 2022: 13 institutionsQ3 2022: 12 institutionsQ4 2022: 15 institutionsQ1 2023: 16 institutionsQ2 2023: 14 institutionsQ3 2023: 17 institutionsQ4 2023: 23 institutionsQ1 2024: 22 institutionsQ2 2024: 22 institutionsQ3 2024: 19 institutionsQ4 2024: 22 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ1 2021: $585.0K
Q1 2021: $585.0KQ2 2021: $2.70MQ3 2021: $2.23MQ4 2021: $1.71MQ1 2022: $1.38MQ2 2022: $794.0KQ3 2022: $768.0KQ4 2022: $1.83MQ1 2023: $820.2KQ2 2023: $725.2KQ3 2023: $682.7KQ4 2023: $2.06MQ1 2024: $3.01MQ2 2024: $2.84MQ3 2024: $1.80MQ4 2024: $1.33MQ1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding CYTH and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 202422$1.33M
Q3 202419$1.80M
Q2 202422$2.84M
Q1 202422$3.01M
Q4 202323$2.06M
Q3 202317$682.7K
Q2 202314$725.2K
Q1 202316$820.2K
Q4 202215$1.83M
Q3 202212$768.0K
Q2 202213$794.0K
Q1 202213$1.38M
Q4 202115$1.71M
Q3 202113$2.23M
Q2 202112$2.70M
Q1 20219$585.0K

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding CYTH in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc33,645$276.0K0.00%––
Geode Capital Management, LLC18,257$149.0K0.00%––
AIGH Capital Management LLC17,235$141.0K0.05%––
Royal Bank of Canada746$6.00K0.00%––
UBS Group AG698$6.00K0.00%––
Morgan Stanley503$4.00K0.00%––
Tower Research Capital LLC (TRC)194$2.00K0.00%––
Captrust Financial Advisors100$1.00K0.00%––
Wells Fargo & Company24$00.00%––